Feedback
Settings

Settings

Goto Application

278,228 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 27,823
1.WO/2025/140565CARRIER PEPTIDE, CONJUGATE COMPRISING CARRIER PEPTIDE, COMPOSITION, PREPARATION METHOD, AND USE
WO - 03.07.2025
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No PCT/CN2024/143219 Applicant SUZHOU RIBO LIFE SCIENCE CO., LTD. Inventor ZHANG, Hongyan
A new carrier peptide and a conjugate comprising the carrier peptide. The length of the carrier peptide is 5-30 amino acid residues, wherein the carrier peptide comprises one or more amino acid sequences I, the length of each amino acid sequence I is independently 5-7 amino acid residues, and each amino acid sequence I is consistent with at least five contiguous amino acid residues set forth in SEQ ID NO: 1: RSLGDTG (SEQ ID NO:1), where each capital letter independently represents an amino acid residue, and each amino acid residue is independently a natural or modified amino acid residue. The carrier peptide can be covalently linked to a functional group to form a conjugate, thereby effectively reaching a target tissue or a target organ in a central nervous system, and exerting a therapeutic and/or diagnostic effect.
2.WO/2025/144525POLYMERIC ION EXCHANGE-REVERSED PHASE-MIXED-MODE CHROMATOGRAPHY STATIONARY PHASE FOR ANALYSIS OF PROTEINS AND NUCLEIC ACIDS
WO - 03.07.2025
Int.Class B01J 20/26
BPERFORMING OPERATIONS; TRANSPORTING
01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
20Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
22comprising organic material
26Synthetic macromolecular compounds
 Appl.No PCT/US2024/056809 Applicant DIONEX CORPORATION Inventor LIEHR, Shanhua Lin
A chromatographic media for separating biopolymers, the chromatographic media having hydrophobic and ionic retention modes, the chromatographic media comprising porous substrate particles including a hydrophobic polymer resin and ion exchange functional groups copolymerized with the hydrophobic polymer resin or grafted to the surface of the porous substrate, wherein the ion exchange functional groups are not greater than about 5 mol% of the porous substrate particles.
3.WO/2025/138610SYNTHESIS PROCESS FOR OLIGONUCLEOTIDE PRIMER
WO - 03.07.2025
Int.Class C07H 1/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
1Processes for the preparation of sugar derivatives
 Appl.No PCT/CN2024/098367 Applicant GENERAL BIOL (ANHUI) CO., LTD. Inventor LIU, Zongwen
The present invention belongs to the technical field of nucleic acid synthesis. Disclosed is a synthesis process for an oligonucleotide primer. The synthesis process comprises the following steps: step 1, adding dried chloromethylated polystyrene resin to toluene, after swelling, adding p-diaminoazobenzene, and performing a reaction at 70℃ under stirring, so as to obtain microspheres; and loading a protection group on the surface of the microspheres to obtain a solid-phase support; step 2, synthesizing a primer: completing the synthesis of the primer on the solid-phase support, so as to obtain a primer crude product, and performing an ammonolysis reaction: putting the solid-phase support containing the primer crude product into an ammonolysis solution and performing ammonolysis, the ammonolysis being carried out alternately under ultraviolet light and visible light; and step 3, purifying the primer.
4.WO/2025/141025NOVEL CAPPING STRATEGIES FOR MRNA 5'CAP
WO - 03.07.2025
Int.Class C07H 19/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
 Appl.No PCT/EP2024/088312 Applicant ELEVEN THERAPEUTICS LTD Inventor DELABARRE, Byron Scott
The present invention relates to synthetic cap analogs useful for the functionalization of mRNAs, which can replace canonical cap structures. Compounds disclosed herein may be functionalized with a polynucleotide using chemical synthesis approaches.
5.WO/2025/140275PHOSPHATE COMPOUND OF SUBSTITUTED PYRAZOLINE AZO DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO - 03.07.2025
Int.Class C07D 231/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
06having one double bond between ring members or between a ring member and a non-ring member
08with oxygen or sulfur atoms directly attached to ring carbon atoms
 Appl.No PCT/CN2024/142200 Applicant JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Inventor GAO, Wan
A phosphate compound of a substituted pyrazoline azo derivative or a pharmaceutically acceptable salt thereof. Specifically, provided are a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has good pharmacokinetic properties, and is beneficial to preparation of formulation forms having better patient compliance.
6.WO/2025/139811NUCLEIC ACID CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 03.07.2025
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
 Appl.No PCT/CN2024/138707 Applicant SUZHOU SIRAN BIOTECHNOLOGY CO., LTD. Inventor YANG, Zhiwei
The present invention relates to a compound for forming a conjugate with an oligonucleotide, the compound having a structure as represented by formula (I). Also provided in the present invention are a corresponding conjugate, and the use of the conjugate in preparing a drug for treating and/or preventing hepatogenic diseases. The delivery molecule disclosed in the present invention uses a saturated cyclic group and a novel linker to serve as a core skeleton to link to a phosphodiester bond, and compared with the prior art, exhibits excellent animal in-vivo bioactivity and long-acting drug efficacy, and also achieves the advantages of cheap raw materials, simple synthesis, feasible process development, good oligonucleotide synthesis efficiency, etc. In addition, the present invention improves the linker between galactosamine and the phosphodiester bond, thereby improving the metabolic stability of the whole delivery molecule and further improving the in-vivo delivery efficiency.
7.WO/2025/141521LIPIDS HAVING DENDRITIC MOIETIES
WO - 03.07.2025
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
 Appl.No PCT/IB2024/063236 Applicant SANOFI Inventor BAZIN, Emilie
Provided herein are dendritic lipids or pharmaceutically acceptable salts thereof. The dendritic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
8.WO/2025/142856CALCIUM SALT OF REDUCED Β-NICOTINAMIDE MONONUCLEOTIDE AND METHOD FOR PRODUCING SAME
WO - 03.07.2025
Int.Class C07H 19/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
 Appl.No PCT/JP2024/045512 Applicant KANEKA CORPORATION Inventor MATSUBARA, Hisanori
The purpose of the present disclosure is to provide, with regard to reduced β-nicotinamide mononucleotide (NMNH), which is expected to exhibit an excellent anti-aging effect, a calcium salt of NMNH as a novel NMNH salt that is easy to distribute and handle and provide a method for producing the calcium salt of NMNH.　One aspect of the present embodiment is a calcium salt of reduced β-nicotinamide mononucleotide.
9.WO/2025/144716NUCLEOTIDES WITH ENZYMATICALLY CLEAVABLE 3'-O-GLYCOSIDE BLOCKING GROUPS FOR SEQUENCING
WO - 03.07.2025
Int.Class C07H 19/067
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
067with ribosyl as the saccharide radical
 Appl.No PCT/US2024/061310 Applicant ILLUMINA, INC. Inventor EMOND, Stephane
Embodiments of the present disclosure relate to nucleotide and nucleoside molecules with 3'-O-glycoside blocking groups. Also provided herein are methods to prepare such nucleotide and nucleoside molecules, and methods and kits for sequencing applications.
10.WO/2025/143262DOUBLE-STRANDED RNA CONTAINING CARBAMOYLETHYL MODIFICATION
WO - 03.07.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/JP2024/046495 Applicant NISSAN CHEMICAL CORPORATION Inventor IRIYAMA Yusuke
The purpose of the present invention is to provide a chemically modified siRNA having further enhanced metabolic stability while maintaining activity.　The present invention provides a double-stranded RNA capable of inhibiting expression of a target RNA, wherein the double-stranded RNA contains a sense strand and an antisense strand, the antisense strand has 14-40 nucleotides and has sufficient complementarity with the target RNA to mediate RNA interference, the sense strand has 14-40 nucleotides and has complementarity with the antisense strand, and the double-stranded RNA contains at least one 2'-O-XCE nucleotide.
# -